JP2000516925A - カリウムチャンネル調節物質であるジフェニルヘテロ環化合物 - Google Patents

カリウムチャンネル調節物質であるジフェニルヘテロ環化合物

Info

Publication number
JP2000516925A
JP2000516925A JP10509180A JP50918098A JP2000516925A JP 2000516925 A JP2000516925 A JP 2000516925A JP 10509180 A JP10509180 A JP 10509180A JP 50918098 A JP50918098 A JP 50918098A JP 2000516925 A JP2000516925 A JP 2000516925A
Authority
JP
Japan
Prior art keywords
chloro
phenyl
hydroxyphenyl
trifluoromethyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP10509180A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000516925A5 (enExample
Inventor
ジェフリー エル ロミン
スコット ダブリュー マーティン
ピレセーナ ヘワワサム
ニコラス エイ ミーンウェル
ヴァレンティン ケイ グリブコッフ
ジョン イー ジュニア スターレット
Original Assignee
ブリストル―マイヤーズ スクイブ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ブリストル―マイヤーズ スクイブ カンパニー filed Critical ブリストル―マイヤーズ スクイブ カンパニー
Publication of JP2000516925A publication Critical patent/JP2000516925A/ja
Publication of JP2000516925A5 publication Critical patent/JP2000516925A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP10509180A 1996-07-31 1997-07-30 カリウムチャンネル調節物質であるジフェニルヘテロ環化合物 Ceased JP2000516925A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2298396P 1996-07-31 1996-07-31
US60/022,983 1996-07-31
PCT/US1997/014352 WO1998004135A1 (en) 1996-07-31 1997-07-30 Diphenyl heterocycles as potassium channel modulators

Publications (2)

Publication Number Publication Date
JP2000516925A true JP2000516925A (ja) 2000-12-19
JP2000516925A5 JP2000516925A5 (enExample) 2005-02-10

Family

ID=21812455

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10509180A Ceased JP2000516925A (ja) 1996-07-31 1997-07-30 カリウムチャンネル調節物質であるジフェニルヘテロ環化合物

Country Status (18)

Country Link
US (3) US5869509A (enExample)
EP (1) EP0915856A4 (enExample)
JP (1) JP2000516925A (enExample)
KR (1) KR20000029735A (enExample)
CN (1) CN1116287C (enExample)
AR (1) AR008110A1 (enExample)
AU (1) AU711736B2 (enExample)
BR (1) BR9710793A (enExample)
CZ (1) CZ32199A3 (enExample)
HU (1) HUP0000063A3 (enExample)
IL (1) IL128308A (enExample)
NO (1) NO990428L (enExample)
NZ (1) NZ334403A (enExample)
PL (1) PL331385A1 (enExample)
RU (1) RU2175319C2 (enExample)
TW (1) TW467902B (enExample)
WO (1) WO1998004135A1 (enExample)
ZA (1) ZA976554B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009125870A1 (en) 2008-04-09 2009-10-15 Mitsubishi Tanabe Pharma Corporation Pyrimidine, pyridine and triazine derivatives as maxi-k channel openers.
JP2022550640A (ja) * 2019-10-07 2022-12-02 ディー．イー．ショウ リサーチ，エルエルシー Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリール複素環式化合物
JP2022552445A (ja) * 2019-10-07 2022-12-15 ディー．イー．ショウ リサーチ，エルエルシー Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリールメチレン芳香族化合物

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW467902B (en) * 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators
ID26909A (id) 1998-01-29 2001-02-15 Bristol Myers Squibb Co Turunan-turunan 1,3,4-oksadiazolon
JP2002501926A (ja) * 1998-01-29 2002-01-22 ブリストル−マイヤーズ スクイブ カンパニー ジアリール１、３、４−オキサジアゾロンのホスフェート誘導体
EP1056730A4 (en) * 1998-01-29 2003-01-02 Bristol Myers Squibb Co Diaryl-1,3,4-oxadiazolone benzoate
JP2003525199A (ja) * 1998-01-29 2003-08-26 ブリストル−マイヤーズ スクイブ カンパニー ジアリール１，３，４−オキサジアゾロンアミノ酸誘導体
DE19816882A1 (de) * 1998-04-17 1999-10-21 Boehringer Ingelheim Pharma Triazolone mit neuroprotektiver Wirkung
US6919366B2 (en) * 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
US6911462B2 (en) * 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
SE9802937D0 (sv) * 1998-09-01 1998-09-01 Astra Pharma Prod Novel compounds
US6632836B1 (en) 1998-10-30 2003-10-14 Merck & Co., Inc. Carbocyclic potassium channel inhibitors
US6194458B1 (en) 1998-10-30 2001-02-27 Merck & Co., Inc. Benzamide potassium channel inhibitors
US6303637B1 (en) * 1998-10-30 2001-10-16 Merck & Co., Inc. Heterocyclic potassium channel inhibitors
US6297241B1 (en) 1999-01-29 2001-10-02 Bristol-Myers Squibb Company Carbamate derivatives of diaryl 1,3,4-oxadiazolone
WO2000044745A1 (en) * 1999-01-29 2000-08-03 Bristol-Myers Squibb Company Carbamate derivatives of diaryl 1,3,4-oxadiazolone
GB9915414D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
US20050153940A1 (en) * 2000-01-26 2005-07-14 Cedars-Sinai Medical Center Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor
US7018979B1 (en) 2000-01-26 2006-03-28 Cedars-Sinai Medical Center Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor
GB2361003A (en) * 2000-04-07 2001-10-10 Astrazeneca Ab Novel compounds
HUP0303559A3 (en) * 2000-10-13 2006-02-28 Bristol Myers Squibb Co Selective maxi-k-potassium channel openers functional under conditions of high intracellular calcium concentration and uses thereof
DE10056344A1 (de) * 2000-11-14 2002-05-16 Degussa n-Propylethoxysiloxane, Verfahren zu deren Herstellung und deren Verwendung
DE10058461A1 (de) * 2000-11-24 2002-09-19 Bayer Ag Substituierte Cyclohexanderivate und ihre Verwendung
US6855829B2 (en) 2001-02-20 2005-02-15 Bristol-Myers Squibb Company 3-fluoro-2-oxindole modulators of KCNQ potassium channels and use thereof in treating migraine and mechanistically related disease
ES2291455T3 (es) * 2001-03-12 2008-03-01 Avanir Pharmaceuticals Compuestos de bencimidazol para modular ige e inhibir la proliferacion celular.
WO2002083111A2 (en) * 2001-04-16 2002-10-24 Tanabe Seiyaku Co., Ltd. Imidazole, thiazole and oxazole derivatives and their use for the manufacture of a medicament for the treatment and/or prevention of pollakiuria or urinary incontinence
US7022480B1 (en) 2001-10-11 2006-04-04 The Regents Of The University Of California Exons of the hSKCa3/KCNN3 gene
US7211561B2 (en) * 2001-10-12 2007-05-01 Cedars-Sinai Medical Center Method for inducing selective cell death of malignant cells by activation of calcium-activated potassium channels (KCa)
US6613786B2 (en) 2001-11-02 2003-09-02 Bristol-Myers Squibb Company Thiophenyl triazol-3-one derivatives as smooth muscle relaxants
US7846671B2 (en) * 2002-01-28 2010-12-07 Bristol-Myers Squibb Company Methods of screening for agents that modulate the interaction of RGS and Gαq and urinary incontinence
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
WO2004024655A2 (en) 2002-09-12 2004-03-25 Avanir Pharmaceuticals Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation
TWI276631B (en) * 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
TWI271402B (en) * 2002-10-15 2007-01-21 Tanabe Seiyaku Co Large conductance calcium-activated K channel opener
TW200505441A (en) 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
RU2005134670A (ru) * 2003-04-10 2006-06-10 Аванир Фармасьютикалс (Us) Производные имидазола для лечения аллергических и гиперпролиферативных нарушений
GB0315111D0 (en) * 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
CA2533990A1 (en) * 2003-08-08 2005-02-17 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
AU2005230867A1 (en) * 2004-03-26 2005-10-20 Amphora Discovery Corporation Certain triazole-based compounds, compositions, and uses thereof
CA2561718A1 (en) * 2004-04-13 2005-10-27 Icagen, Inc. Polycyclic pyridines as potassium ion channel modulators
EP1773790B1 (en) * 2004-07-27 2012-08-15 F.Hoffmann-La Roche Ag Benzyltriazolone compounds as non-nucleoside reverse transcriptase inhibitors
US8293778B2 (en) 2004-07-27 2012-10-23 Roche Palo Alto Llc Heterocyclic antiviral compounds
CA2583177A1 (en) * 2004-10-13 2006-04-27 Ptc Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
DK1817295T3 (da) 2004-11-18 2013-02-18 Synta Pharmaceuticals Corp Triazolforbindelser, der modulerer HSP90-aktivitet
WO2006091542A2 (en) * 2005-02-22 2006-08-31 Cedars-Sinai Medical Center Use of sildenafil, vardenafil and other 5-phosphodiesterase inhibitors to enhance permeability of the abnormal blood-brain barrier
JP5178515B2 (ja) 2005-08-12 2013-04-10 シンタ ファーマシューティカルズ コーポレーション Ｈｓｐ９０活性を調節するピラゾール化合物
US8629285B2 (en) * 2005-08-18 2014-01-14 Synta Pharmaceuticals Corp. Imidazole compounds that modulate HSP90 activity
CA2618628C (en) * 2005-08-18 2014-11-18 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
DE102006024024A1 (de) * 2006-05-23 2007-11-29 Bayer Healthcare Aktiengesellschaft Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung
AU2007267852A1 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Compounds that modulate Hsp90 activity and methods for identifying same
TW200804314A (en) 2006-05-25 2008-01-16 Synta Pharmaceuticals Corp Triazole compounds that modulate Hsp90 activity
AU2007267847B2 (en) * 2006-05-25 2012-04-12 Synta Pharmaceuticals Corp. Triazole compounds that modulate Hsp90 activity
JP5410965B2 (ja) * 2006-05-25 2014-02-05 シンタ ファーマシューティカルズ コーポレーション Ｈｓｐ９０活性を調節するトリアゾール化合物
EP2121640A1 (en) * 2007-01-18 2009-11-25 NeuroSearch AS Novel semicarbazide and carbonylhydrazide derivatives useful as potassium channel modulators
BRPI0809617A2 (pt) 2007-03-29 2014-09-16 Hoffmann La Roche Inibidores não-nucleosídicos da transcriptase reversa
WO2008135447A1 (en) * 2007-05-03 2008-11-13 Neurosearch A/S Acetamide derivatives as potassium channel modulators
US20090281089A1 (en) * 2008-04-11 2009-11-12 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
PE20091953A1 (es) * 2008-05-08 2010-01-09 Du Pont Azoles sustituidos como fungicidas
US9205086B2 (en) 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
WO2013067165A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with platinum-containing agents
US9439899B2 (en) 2011-11-02 2016-09-13 Synta Pharmaceuticals Corp. Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors
US9402831B2 (en) 2011-11-14 2016-08-02 Synta Pharmaceutical Corp. Combination therapy of HSP90 inhibitors with BRAF inhibitors
EP2822931B1 (en) 2012-03-09 2017-05-03 Inception 2, Inc. Triazolone compounds and uses thereof
DK2935228T3 (en) 2012-12-20 2017-10-30 Inception 2 Inc TRIAZOLONE COMPOUNDS AND APPLICATIONS THEREOF
JP2016529311A (ja) 2013-09-06 2016-09-23 インセプション ２、 インコーポレイテッド トリアゾロン化合物類及びそれらの使用
US10681909B2 (en) 2014-08-29 2020-06-16 Fmc Corporation Herbicidal triazoles
CN104710379B (zh) * 2015-03-09 2017-01-18 华南理工大学 一种bms‑191011的合成方法
US12194026B2 (en) * 2018-10-26 2025-01-14 University Of South Florida Drug for treating tinnitus
CN115504940A (zh) * 2021-06-23 2022-12-23 中国科学院上海药物研究所 一种酰胺类化合物、其制备方法和制药用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1545646B1 (de) * 1965-12-15 1969-09-18 Boehringer Sohn Ingelheim 1,3-Dimethyl-4-(2',4'-dichlorphenyl)-1,2,4-triazolon-(5) und Verfahren zu dessen Herstellung
CH583213A5 (enExample) * 1973-05-21 1976-12-31 Ciba Geigy Ag
DE2940709A1 (de) * 1979-10-08 1981-04-16 Basf Ag, 6700 Ludwigshafen Verfahren zur herstellung von in 1-stellung substituierten imidazolen
US5436252A (en) * 1986-12-19 1995-07-25 Merrell Dow Pharmaceuticals Inc. 5-aryl-3H-1,2,4-triazol-3-ones and their use in the treatment of neurodegenerative disorders
CA2014537A1 (en) * 1989-04-26 1990-10-26 Yoshio Hayashi 4-imidazoline derivatives
US4966909A (en) * 1989-12-20 1990-10-30 Merrell Dow Pharmaceuticals 4-benzyl-5-phenyl-2,4-dihydro-3H-1,2,4-triazol-3-ones and their use as anticonvulsants
US5331002A (en) * 1990-04-19 1994-07-19 Merrell Dow Pharmaceuticals Inc. 5-aryl-4-alkyl-3H-1,2,4-triazole-3-thiones useful as memory enhancers
DE4015535A1 (de) * 1990-05-15 1991-11-21 Basf Ag Verfahren zur herstellung von n-substituierten imidazolen
IL99372A0 (en) * 1990-09-10 1992-08-18 Ciba Geigy Ag Azacyclic compounds
IT1251488B (it) * 1991-09-17 1995-05-15 Mini Ricerca Scient Tecnolog Ossa(tia)diazol- e triazol-oni(tioni) ad attivita' acaricida ed insetticida
US5234947A (en) * 1991-11-07 1993-08-10 New York University Potassium channel activating compounds and methods of use thereof
DK28893D0 (da) * 1993-03-15 1993-03-15 Neurosearch As Benzimidazole derivater, deres fremstilling og anvendelse
US5612363A (en) * 1995-06-02 1997-03-18 Berlex Laboratories, Inc. N,N-di(aryl) cyclic urea derivatives as anti-coagulants
IL124364A (en) * 1995-11-09 2001-08-08 Synthelabo 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol -2(3h)- one derivatives, their preparation and pharmaceutical compositions comprising them
TW467902B (en) * 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009125870A1 (en) 2008-04-09 2009-10-15 Mitsubishi Tanabe Pharma Corporation Pyrimidine, pyridine and triazine derivatives as maxi-k channel openers.
US8575338B2 (en) 2008-04-09 2013-11-05 Mitsubishi Tanabe Pharma Corporation Pyrimidine, pyridine and triazine derivatives as maxi-K channel openers
JP2022550640A (ja) * 2019-10-07 2022-12-02 ディー．イー．ショウ リサーチ，エルエルシー Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリール複素環式化合物
JP2022552445A (ja) * 2019-10-07 2022-12-15 ディー．イー．ショウ リサーチ，エルエルシー Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリールメチレン芳香族化合物
JP7697954B2 (ja) 2019-10-07 2025-06-24 ディー．イー．ショウ リサーチ，エルエルシー Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリールメチレン芳香族化合物

Also Published As

Publication number Publication date
NO990428D0 (no) 1999-01-29
AU711736B2 (en) 1999-10-21
BR9710793A (pt) 1999-08-17
US6271249B1 (en) 2001-08-07
HUP0000063A3 (en) 2001-04-28
EP0915856A1 (en) 1999-05-19
NZ334403A (en) 2000-09-29
US6077861A (en) 2000-06-20
TW467902B (en) 2001-12-11
ZA976554B (en) 1999-01-25
KR20000029735A (ko) 2000-05-25
WO1998004135A1 (en) 1998-02-05
HUP0000063A2 (hu) 2001-01-29
NO990428L (no) 1999-01-29
EP0915856A4 (en) 2006-04-12
IL128308A (en) 2004-09-27
IL128308A0 (en) 1999-11-30
PL331385A1 (en) 1999-07-05
CN1226803A (zh) 1999-08-25
US5869509A (en) 1999-02-09
AU4067997A (en) 1998-02-20
CZ32199A3 (cs) 1999-06-16
CN1116287C (zh) 2003-07-30
AR008110A1 (es) 1999-12-09
RU2175319C2 (ru) 2001-10-27

Similar Documents

Publication Publication Date Title
JP2000516925A (ja) カリウムチャンネル調節物質であるジフェニルヘテロ環化合物
US7304062B2 (en) Peroxisome proliferator activated receptor alpha agonists
JP3290657B2 (ja) アンギオテンシンｉｉ拮抗剤として活性な酸性アラルキルトリアゾール誘導体
TWI772295B (zh) 經醯胺-取代的吡啶基三唑衍生物及其用途
US5336778A (en) Substituted triazoles as angiotensin II antagonists
PT2027096E (pt) Imidazolonas e triazolonas aril-substituídas enquanto inibidores dos receptores de vasopressina
PT1133474E (pt) Derivados da 4-arilquinolin-2-ona substituidos em 3 posições utilizados como moduladores do canal de potássio.
JP2002527352A (ja) １，３，４−オキサジアゾロン誘導体
JP3086692B2 (ja) 抗炎症剤としてのフエナメート１，３，４‐チアジアゾール類および１，３，４‐オキサジアゾール類
MXPA00009474A (es) Nuevos heterociclos de 5 anillos sustituidos con difenilo, procedimientos para su preparacion, asi como su empleo como medicamentos.
JP2002501926A (ja) ジアリール１、３、４−オキサジアゾロンのホスフェート誘導体
KR20130138216A (ko) 치환된 ｎ-펜에틸트리아졸론아세트아미드 및 그의 용도
AU736712B2 (en) Benzoate derivatives of diaryl 1,3,4-oxadiazolone
BR112020007983A2 (pt) pró-fármacos de derivados de triazol substituído e usos dos mesmos
US5856350A (en) 3-phenyl-1,4-dialkyl-1,2,4-triazolium salts and their use as antidepressants
HK1022247A (en) Diphenyl heterocycles as potassium channel modulators
MXPA99000964A (en) Diphenyl heterocycles as potassium channel modulators
EP3375784A1 (en) Aza-dihydro-acridone derivatives
JP2003525199A (ja) ジアリール１，３，４−オキサジアゾロンアミノ酸誘導体
JP2002535402A (ja) ジアリール１，３，４−オキサジアゾロンカーバメート誘導体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040423

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040423

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071204

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20080508

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080624